Richard Kefford

103.6k citations

354 papers · 20.4k indexed · 7 hit papers · h-index 74

Oncology top 0.05%
Molecular Biology top 0.2%
Immunology top 0.5%
Cancer Research top 0.5%
Pulmonary and Respiratory Medicine top 0.5%

Co-authors: Georgina V. Long Richard A. Scolyer John F. Thompson Helen Rizos Alexander M. Menzies Matteo S. Carlino Graham J. Mann Lauren E. Haydu
Topics: Melanoma and MAPK Pathways (158 papers)Cutaneous Melanoma Detection and Management (96 papers)Cancer Immunotherapy and Biomarkers (63 papers)
Cited by: Oncology Immunology Cancer Research
Journals: Nature Cell Proceedings of the National Academy of Sciences
Partner nations: Australia United States France

In The Last Decade

Richard Kefford

352 papers receiving 20.1k citations

Hit Papers

5 papers align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Prognostic and Clinicopathologic Associations of Oncogenic BRAF in Metastatic Melanoma

2011 794 citations Georgina V. Long, Alexander M. Menzies et al. Journal of Clinical Oncology profile →
Dabrafenib in patients with melanoma, untreated brain metastases, and other solid tumours: a phase 1 dose-escalation trial

2012 719 citations Gerald S. Falchook, Georgina V. Long et al. profile →
Acquired Resistance and Clonal Evolution in Melanoma during BRAF Inhibitor Therapy

2013 715 citations Hubing Shi, Willy Hugo et al. Cancer Discovery profile →
Five-year survival outcomes for patients with advanced melanoma treated with pembrolizumab in KEYNOTE-001

2019 638 citations Omid Hamid, Caroline Robert et al. profile →
Selective BRAF Inhibitors Induce Marked T-cell Infiltration into Human Metastatic Melanoma

2011 507 citations James S. Wilmott, Georgina V. Long et al. Clinical Cancer Research profile →
Melanoma whole-exome sequencing identifies V600EB-RAF amplification-mediated acquired B-RAF inhibitor resistance

2012 470 citations Hubing Shi, Gatien Moriceau et al. profile →
BRAF Inhibitor Resistance Mechanisms in Metastatic Melanoma: Spectrum and Clinical Impact

2014 382 citations Helen Rizos, Alexander M. Menzies et al. Clinical Cancer Research profile →

Peers

Countries citing papers authored by Richard Kefford

Since Specialization

Citations

This map shows the geographic impact of Richard Kefford's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Richard Kefford with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Richard Kefford more than expected).

Fields of papers citing papers by Richard Kefford

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Richard Kefford. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Richard Kefford. The network helps show where Richard Kefford may publish in the future.

Co-authorship network of co-authors of Richard Kefford

This figure shows the co-authorship network connecting the top 25 collaborators of Richard Kefford. A scholar is included among the top collaborators of Richard Kefford based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Richard Kefford. Richard Kefford is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Longitudinal Monitoring of ctDNA in Patients with Melanoma and Brain Metastases Treated with Immune Checkpoint Inhibitors 2020 ·Clinical Cancer Research ·Jenny Lee,Alexander M. Menzies,Matteo S. Carlino,Ashleigh C. McEvoy,Shahneen Sandhu,Alison M. Weppler,Russell J. Diefenbach,Sarah‐Jane Dawson,Richard Kefford,Michael Millward,(unknown),(unknown),Elin S. Gray,Stephen Q. Wong,Richard A. Scolyer,Georgina V. Long,Helen Rizos	62
2	bcGST—an interactive bias-correction method to identify over-represented gene-sets in boutique arrays 2018 ·Bioinformatics ·Kevin Wang,Alexander M. Menzies,Inês Pires da Silva,James S. Wilmott,Yibing Yan,Matthew Wongchenko,Richard Kefford,Richard A. Scolyer,Georgina V. Long,Garth Tarr,(unknown),Jean Yang	1
3	Circulating Cytokines Predict Immune-Related Toxicity in Melanoma Patients Receiving Anti-PD-1–Based Immunotherapy 2018 ·Clinical Cancer Research ·Su Yin Lim,Jenny Lee,Tuba N. Gide,Alexander M. Menzies,Alexander Guminski,Matteo S. Carlino,Edmond J. Breen,Jean Yang,Shila Ghazanfar,Richard Kefford,Richard A. Scolyer,Georgina V. Long,Helen Rizos	271
4	Dynamic Changes in PD-L1 Expression and Immune Infiltrates Early During Treatment Predict Response to PD-1 Blockade in Melanoma 2017 ·Clinical Cancer Research ·Ricardo E. Vilain,Alexander M. Menzies,James S. Wilmott,Hojabr Kakavand,Jason Madore,Alexander Guminski,Elizabeth Liniker,Benjamin Y. Kong,Adam Cooper,Julie R. Howle,Robyn P.M. Saw,Valerie Jakrot,Serigne Lo,John F. Thompson,Matteo S. Carlino,Richard Kefford,Georgina V. Long,Richard A. Scolyer	191
5	Durable Complete Response After Discontinuation of Pembrolizumab in Patients With Metastatic Melanoma 2017 ·Journal of Clinical Oncology ·Caroline Robert,Antoni Ribas,Omid Hamid,Adil Daud,Jedd D. Wolchok,Anthony M. Joshua,Wen-Jen Hwu,Jeffrey S. Weber,Tara C. Gangadhar,Richard W. Joseph,Roxana Dronca,Amita Patnaik,Hassane M. Zarour,Richard Kefford,Peter Hersey,Jin Zhang,James R. Anderson,Scott J. Diede,Scot Ebbinghaus,F. Stephen Hodi	336
6	PD-L1 Expression and Immune Escape in Melanoma Resistance to MAPK Inhibitors 2017 ·Clinical Cancer Research ·Hojabr Kakavand,Robert V. Rawson,Gulietta M. Pupo,Jean Yang,Alexander M. Menzies,Matteo S. Carlino,Richard Kefford,Julie R. Howle,Robyn P.M. Saw,John F. Thompson,James S. Wilmott,Georgina V. Long,Richard A. Scolyer,Helen Rizos	63
7	Dose Escalation of Tamoxifen in Patients with Low Endoxifen Level: Evidence for Therapeutic Drug Monitoring—The TADE Study 2016 ·Clinical Cancer Research ·Peter Fox,Rosemary L. Balleine,(unknown),Bo Gao,Bavanthi Balakrishnar,Alexander M. Menzies,(unknown),Sayed Ali,Val Gebski,Pamela Provan,Sally Coulter,Christopher Liddle,Rina Hui,Richard Kefford,Jodi Lynch,Mark Wong,Nicholas Wilcken,Howard Gurney	64
8	PD ‐L1 expression in melanoma shows marked heterogeneity within and between patients: implications for anti‐ PD ‐1/ PD ‐ L 1 clinical trials 2014 ·Pigment Cell & Melanoma Research ·Jason Madore,Ricardo E. Vilain,Alexander M. Menzies,Hojabr Kakavand,James S. Wilmott,Jessica Hyman,Jennifer H. Yearley,Richard Kefford,John F. Thompson,Georgina V. Long,Peter Hersey,Richard A. Scolyer	333
9	Preexisting MEK1P124 Mutations Diminish Response to BRAF Inhibitors in Metastatic Melanoma Patients 2014 ·Clinical Cancer Research ·Matteo S. Carlino,Carina Fung,Hamideh Shahheydari,Jason R. Todd,Suzanah C. Boyd,Mal Irvine,Adnan Nagrial,Richard A. Scolyer,Richard Kefford,Georgina V. Long,Helen Rizos	53
10	BRAF Inhibitor Resistance Mechanisms in Metastatic Melanoma: Spectrum and Clinical Impactbreakdown → 2014 ·Clinical Cancer Research ·Helen Rizos,Alexander M. Menzies,Gulietta M. Pupo,Matteo S. Carlino,Carina Fung,Jessica Hyman,Lauren E. Haydu,Branka Mijatov,Therese M. Becker,Suzanah C. Boyd,Julie R. Howle,Robyn P.M. Saw,John F. Thompson,Richard Kefford,Richard A. Scolyer,Georgina V. Long	382
11	Tumor Genetic Analyses of Patients with Metastatic Melanoma Treated with the BRAF Inhibitor Dabrafenib (GSK2118436) 2013 ·Clinical Cancer Research ·Katherine L. Nathanson,Anne‐Marie Martin,Bradley Wubbenhorst,Joel Greshock,Richard Letrero,Kurt D’Andrea,Steven O’Day,Jeffrey R. Infante,Gerald S. Falchook,Hendrik‐Tobias Arkenau,Michael Millward,Michael P. Brown,Anna C. Pavlick,Michael A. Davies,Bo Ma,Robert Gagnon,(unknown),Peter F. Lebowitz,Richard Kefford,Georgina V. Long	132
12	Acquired Resistance and Clonal Evolution in Melanoma during BRAF Inhibitor Therapybreakdown → 2013 ·Cancer Discovery ·Hubing Shi,Willy Hugo,Xiangju Kong,Aayoung Hong,Richard C. Koya,Gatien Moriceau,Thinle Chodon,Rongqing Guo,Douglas B. Johnson,Kimberly B. Dahlman,Mark C. Kelley,Richard Kefford,Bartosz Chmielowski,John A. Glaspy,Jeffrey A. Sosman,Nicolas van Baren,Georgina V. Long,Antoni Ribas,Roger S. Lo	715
13	Antiproliferative Effects of Continued Mitogen-Activated Protein Kinase Pathway Inhibition following Acquired Resistance to BRAF and/or MEK Inhibition in Melanoma 2013 ·Molecular Cancer Therapeutics ·Matteo S. Carlino,Kavitha Gowrishankar,Catherine A.B. Saunders,Gulietta M. Pupo,(unknown),Xu Dong Zhang,Robyn P.M. Saw,Therese M. Becker,Richard Kefford,Georgina V. Long,Helen Rizos	61
14	A Novel AKT1 Mutant Amplifies an Adaptive Melanoma Response to BRAF Inhibition 2013 ·Cancer Discovery ·Hubing Shi,Aayoung Hong,Xiangju Kong,Richard C. Koya,Chunying Song,Gatien Moriceau,Willy Hugo,Clarissa C. Yu,Charles Ng,Thinle Chodon,Richard A. Scolyer,Richard Kefford,Antoni Ribas,Georgina V. Long,Roger S. Lo	133
15	Phase II Study of the MEK1/MEK2 Inhibitor Trametinib in Patients With Metastatic BRAF -Mutant Cutaneous Melanoma Previously Treated With or Without a BRAF Inhibitor 2012 ·Journal of Clinical Oncology ·Kevin B. Kim,Richard Kefford,Anna C. Pavlick,Jeffrey R. Infante,Antoni Ribas,Jeffrey A. Sosman,Leslie A. Fecher,Michael Millward,Grant A. McArthur,Patrick Hwu,René González,Patrick A. Ott,Georgina V. Long,Olivia Gardner,Danièle Ouellet,Yanmei Xu,Douglas J. DeMarini,Ngocdiep T. Le,Kiran Patel,Karl D. Lewis	356
16	Distinguishing Clinicopathologic Features of Patients with V600E and V600K BRAF -Mutant Metastatic Melanoma 2012 ·Clinical Cancer Research ·Alexander M. Menzies,Lauren E. Haydu,Lydia Visintin,Matteo S. Carlino,Julie R. Howle,John F. Thompson,Richard Kefford,Richard A. Scolyer,Georgina V. Long	327
17	Phase III Trial of Carboplatin and Paclitaxel With or Without Sorafenib in Metastatic Melanoma 2012 ·Journal of Clinical Oncology ·Keith T. Flaherty,Sandra J. Lee,Fengmin Zhao,Lynn M. Schuchter,Lawrence E. Flaherty,Richard Kefford,Michael B. Atkins,Philip D. Leming,John M. Kirkwood	160
18	Preexisting MEK1 Exon 3 Mutations in V600E/K BRAF Melanomas Do Not Confer Resistance to BRAF Inhibitors 2012 ·Cancer Discovery ·Hubing Shi,Gatien Moriceau,Xiangju Kong,Richard C. Koya,Ramin Nazarian,Gulietta M. Pupo,Antonella Bacchiocchi,Kimberly B. Dahlman,Bartosz Chmielowski,Jeffrey A. Sosman,Ruth Halaban,Richard Kefford,Georgina V. Long,Antoni Ribas,Roger S. Lo	75
19	Selective BRAF Inhibitors Induce Marked T-cell Infiltration into Human Metastatic Melanomabreakdown → 2011 ·Clinical Cancer Research ·James S. Wilmott,Georgina V. Long,Julie R. Howle,Lauren E. Haydu,Raghwa Sharma,John F. Thompson,Richard Kefford,Peter Hersey,Richard A. Scolyer	507
20	Clinical and Biological Efficacy of Recombinant Human Interleukin-21 in Patients with Stage IV Malignant Melanoma without Prior Treatment: A Phase IIa Trial 2009 ·Clinical Cancer Research ·Ian D. Davis,(unknown),Richard Kefford,Michael Millward,Jonathan Cebon,Birte K. Skrumsager,Ulrik Mouritzen,Lasse Tengbjerg Hansen,Kresten Skak,Dorthe Lundsgaard,Klaus Stensgaard Frederiksen,Paul E.G. Kristjansen,Grant A. McArthur	120

About Richard Kefford

Richard Kefford is a scholar working on Oncology, Molecular Biology and Cancer Research, having authored 354 papers that have together received 20.4k indexed citations. Recurring topics across this work include Melanoma and MAPK Pathways (158 papers), Cutaneous Melanoma Detection and Management (96 papers) and Cancer Immunotherapy and Biomarkers (63 papers). The work is most often cited by research in Oncology (13.9k citations), Immunology (4.0k citations) and Cancer Research (2.7k citations). Richard Kefford has collaborated with scholars based in Australia, United States and France. Frequent co-authors include Georgina V. Long, Richard A. Scolyer, John F. Thompson, Helen Rizos, Alexander M. Menzies, Matteo S. Carlino, Graham J. Mann, Lauren E. Haydu, Peter Hersey and Antoni Ribas. Their work appears in journals such as Nature, Cell and Proceedings of the National Academy of Sciences.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact